2. Academic Validation
  3. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types

The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types

  • Cancer. 2020 Jul 15;126(14):3192-3201. doi: 10.1002/cncr.32909.
Hermann Einsele 1,  Hossein Borghaei 2,  Robert Z Orlowski 3,  Marion Subklewe 4,  Gail J Roboz 5,  Gerhard Zugmaier 6,  Peter Kufer 6,  Karim Iskander 7,  Hagop M Kantarjian 8
Affiliations

Affiliations

  • 1 Department of Internal Medicine II, Universität Würzburg, Würzburg, Germany.
  • 2 Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • 3 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 4 Department of Medicine III, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany.
  • 5 Weill Cornell Medicine, Division of Hematology and Oncology, The New York Presbyterian Hospital, New York, New York.
  • 6 Amgen Research (Munich) GmbH, Munich, Germany.
  • 7 Amgen Inc., Thousand Oaks, California.
  • 8 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
PMID: 32401342 DOI: 10.1002/cncr.32909
Abstract

Immuno-oncology therapies engage the immune system to treat Cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target Other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate Cancer, glioblastoma, gastric Cancer, and small-cell lung Cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with Other treatments.

Keywords

B cell; T cell; blinatumomab; hematologic malignancies; tumor-specific antigen.

Figures
Products